EIDD-2749

EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV) . EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses[1][2][3].

Product Specifications

CAS Number

[1613589-24-4]

Product Name Alternative

4'-FlU; 4'-Fluorouridine

UNSPSC

12352005

Target

HCV; RSV; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/eidd-2749.html

Purity

99.86

Solubility

DMSO : 25 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NC(N([C@@H]2O[C@@](CO)(F)[C@@H](O)[C@H]2O)C=C1)=O

Molecular Formula

C9H11FN2O6

Molecular Weight

262.19

References & Citations

[1]Sourimant J, et al. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022 Jan 14;375 (6577) :161-167. |[2]Abas AH, et al. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review [version 1; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2022, 11:410. |[3]George R. Painter, et al. 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. Patent WO2019173602A1.